Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience

por Weinbergerová, Barbora, Čerňan, Martin, Kabut, Tomáš, Semerád, Lukáš, Podstavková, Natália, Szotkowski, Tomáš, Ježíšková, Ivana, Mayer, Jirí
Publicado 2023

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel

por Šestáková, Šárka, Cerovská, Ela, Šálek, Cyril, Kundrát, Dávid, Ježíšková, Ivana, Folta, Adam, Mayer, Jiří, Ráčil, Zdeněk, Cetkovský, Petr, Remešová, Hana
Publicado 2022

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE

por Semerad, Lukas, Žáčková, Daniela, Belohlavkova, Petra, Voglova, Jaroslava, Žák, Pavel, Faber, Edgar, Papajik, Tomas, Skoumalova, Ivana, Karas, Michal, Jindra, Pavel, Klamová, Hana, Salek, Cyril, Srbová, Dana, Zizkova, Hana, Stejskal, Lukas, Cerna, Olga, Cmunt, Eduard, Cicatkova, Petra, Kvetkova, Anezka, Hornak, Tomas, Jeziskova, Ivana, Jurcek, Tomas, Weinbergerová, Barbora, Prochazkova, Jirina, Machova Polakova, Katerina, Svobodnik, Adam, Stepanova, Radka, Mayer, Jiri
Publicado 2023